What pharmacologists can learn from recent advances in estrogen signalling

Research output: Contribution to journalReview article

189 Scopus citations

Abstract

The discovery of the second estrogen receptor (ER) in 1995 surprised many endocrinologists and resulted in some scepticism regarding its physiological importance. However, 8 years later, it is clear that the multiple actions of estrogen in the body are mediated by two receptors that, although similar, are distinct gene products with non-overlapping functions. This clear delineation of the functions of the two receptors in such a short time was made possible by the development of ERα and ERβ knockout mice. The distinct patterns of tissue distribution of these two receptors has heightened interest in novel estrogen targets in the body and has led to awareness of new sites for pharmacological intervention in diseases such as depression, prostate dysfunction, leukaemia, inflammatory bowel disease and colon cancer.

Original languageEnglish (US)
Pages (from-to)479-485
Number of pages7
JournalTrends in Pharmacological Sciences
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'What pharmacologists can learn from recent advances in estrogen signalling'. Together they form a unique fingerprint.

Cite this